Although the relationship between schizophrenia spectrum disorder (SSD) and autism spectrum disorder (ASD) has long been debated, it has not yet been fully elucidated. To address this issue, we took advantage of dual (ASD and SSD) classifiers that discriminate patients from their controls based on resting state brain functional connectivity. An SSD classifier using sophisticated machine-learning algorithms that automatically selected SSDspecific functional connections was applied to Japanese datasets including adult patients with SSD in a chronic stage. We demonstrated good performance of the SSD classification for independent validation cohorts. The generalizability was tested by USA and European cohorts in a chronic stage, and one USA cohort including first episode schizophrenia. The specificity was tested by two adult Japanese cohorts of ASD and major depressive disorder, and one European cohort of attention-deficit hyperactivity disorder. The weighted linear summation of the classifier's functional connections constituted the biological dimensions representing neural liability to the disorders. Our previously developed robust ASD classifier constituted the ASD dimension. Distributions of individuals with SSD, ASD and healthy controls were examined on the SSD and ASD biological dimensions. The SSD and ASD populations exhibited overlapping but asymmetrical patterns on the two biological dimensions. That is, the SSD population showed increased liability on the ASD dimension, but not vice versa. Furthermore, the two dimensions were correlated within the ASD population but not the SSD population. Using the two biological dimensions based on resting-state functional connectivity enabled us to quantify and visualize the relationships between SSD and ASD.
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Introduction
The relationship between schizophrenia and autism is a matter of historical and long-lasting debate. In 1911, Eugen Bleuler regarded autism as one of the fundamental symptoms in schizophrenia 1 . No clear distinction between schizophrenia and autism had been described by the presentation of Diagnostic and Statistical Manual of Mental Disorders (DSM)-II in 1968. In the mid-60s to 70s, epidemiological studies concluded that these two conditions were distinct and unrelated. However, recent biological studies showed overlapping relationships and commonalities between the two disorders 2, 3 . Genetic studies demonstrated common loci and pathways, suggesting that autism spectrum disorder (ASD) overlaps with schizophrenia spectrum disorder (SSD) 4, 5 . Brain structural magnetic resonance imaging (MRI) and functional MRI studies also reported common abnormalities in gray matter volumes 6 and brain activations 7, 8 . Nevertheless, the relationship between SSD and ASD remains controversial 2 .
The fundamental problems behind this issue are that we lack a reliable biological identification for these disorders and that the diagnosis is based mostly on a symptomatological and categorical approach as represented by DSM. DSM criteria are mainly based on the patient's behavioral signs and symptoms 9 , although the symptoms in patients with SSD and ASD, respectively, are heterogeneous and vary erratically over time 10, 11 . Hence, there is an explanatory gap between phenomenological entities and neurobiological underpinnings. To bridge this explanatory gap, researchers have begun to use a dimensional approach advocated by the National Institute of Mental Health Research Domain Criteria 12 .
The dimensional approach involves exploratory analysis with a vast amount of data 13 , and therefore its constructs at the moment are distant from the level of "the actual clinical phenomena that bring patients to the clinic 14, 15 ".
To solve the problems detailed above and to unravel the relationship between SSD and ASD, we propose a novel approach that reconciles categorical and dimensional approaches, that is, establishment of biological dimensions that are also compatible with DSM-based categorical diagnostic labels. We recruited individuals with ASD and SSD according to DSM. Next, we developed ASD and SSD classifiers using sophisticated machine-learning algorithms from brain functional connectivity (FC) measured by resting-state fMRI (rs-fMRI), based on the reports that ASD [16] [17] [18] [19] [20] [21] and SSD [22] [23] [24] [25] [26] [27] [28] [29] exhibited FC abnormalities in rs-fMRI. The classifiers for biological dimensions must be robust enough to have generalizability to independent cohorts with different ethnicities or MRI machine vendors. We have already developed the ASD classifier that has generalizability to perfectly independent validation cohorts 30 , and here, we developed a similarly generalizable SSD classifier using the same machine-learning methods.
Furthermore, we determined each biological dimension from the weighted linear summation of functional connections of SSD and ASD classifiers, and plotted individuals with ASD, SSD, and healthy controls (HCs) on the SSD-ASD dimensions. Finally, visualizing and quantifying each individual in a relative manner, we could verify the relationship between SSD and ASD populations. (Table S2 ). 
Methods

Participants and MRI data acquisition
Preprocessing of MR images
Selecting FCs as SSD classifier
To develop an SSD classifier from the correlation matrices, we adopted a cascade of L 1 -norm regularized sparse canonical correlation analysis (L 1 -SCCA) 31 and sparse logistic regression (SLR) 32 to select SSD-specific FCs while minimizing the effects of over-fitting and nuisance variables. The selection of SSD-specific FCs and classification performance evaluation were carried out through a sequential process of 9 x 9 nested feature-selection and leave-one-out cross-validation (LOOCV). The machine-learning algorithms automatically selected [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] FCs from about 10,000 FCs of whole brain rs-fMRI. certainty for SSD or ASD, a large negative value for high certainty for HC, and values near zero indicate uncertainty. Consequently, the WLS distributions based on functional brain connectivity probabilistically determined the neural liability to ASD and SSD as well as candidate genes for the disorders determined the genetic liability. Thus, we here named the WLS value "neural liability". In the beginning of applying the machine-learning algorithm to patient and HC populations, we employed the binary value (patient or HC) of categorical diagnosis, and at the end of this process, we generated the continuous probabilistic degree of diagnostic certainty as an objective neural liability. Then, we utilized the neural liability as a biological dimension. In this way, we could integrate the categorical and dimensional approaches. (Figure S1 and Supplementary Methods).
The performance of the classifier was expressed in terms of area under the curve (AUC), accuracy, sensitivity, and specificity. The statistical significance of classification was assessed by permutation test 33 .
Generalizability of the Kyoto classifier
We tested the generalizability of the Kyoto classifier to three independent cohorts, COBRE 
Specificity of the Kyoto classifier
We tested the specificity of the Kyoto classifier, applying the classifier to two additional Japanese cohorts of ASD and major depressive disorder (MDD), respectively, and one European cohort of attention-deficit hyperactivity disorder (ADHD) (Supplementary Methods). The datasets of ASD, ADHD, and MDD were scanned on 3T MRI system. Details of their demographic information and MRI parameters are shown in the referred study 30 . The other disorder's datasets (ASD, ADHD, and MDD) were preprocessed in the same manner as 
MDD:
A total of 104 patients with MDD and 143 age-matched HC were examined. The patients were recruited from a local clinic and the healthy controls from the community of the Hiroshima University.
Relationships between SSD and ASD on the two biological dimensions
Japanese individuals with SSD, ASD, and HC were plotted on the SSD-ASD dimensional plane. The SSD and ASD dimensional scores are the WLS using the SSD and ASD classifiers, respectively. The ASD classifier was taken from our previous study 30 
Results
Accurate SSD classifier for Kyoto discovery cohort
The 16 FCs incorporated in our final classifier were selected by the sparse logistic regression (SLR) using the whole Kyoto datasets. The identified FCs showed the robustness and stability of across the cross-validation procedure ( Figure S2 ). The classifier differentiated SSD from HC populations with an accuracy of 76% and an AUC of 0.83 (permutation test, P = 0.006; see Table 1 and Figure S3 ). We calculated the WLS of each participant from the 16
FCs. The two WLS distributions of the SSD and HC populations were clearly separated by a threshold of WLS = 0 ( Fig. 1a ). We found that high classification accuracy was not only achieved for the entire datasets, but also for the two sites separately (the accuracies of Kyoto A and B were 74% and 77%, respectively) ( Table 1 and Figure S4 ). When tested on the COBRE dataset, the Kyoto classifier achieved high performance, with an accuracy of 70% (AUC=0.75) ( Table 1 and Fig. 1b ). The probability of obtaining this high performance by chance is as small as P = 0.001 (permutation test, see Figure S3 ). For UMCU-TOPFIT ( Fig.   1c ), the classifier also achieved accuracy of 61% (AUC=0.66) (P = 0.031, permutation test), although this classification performance for UMCU-TOPFIT was lower than for COBRE.
For JHU-FES ( Fig. 1d ), the AUC (0.42) was below the chance level (Table 1) , and thus generalization was not observed.
Characteristics of 16 identified FCs in the SSD classifier
The 16 FCs as SSD classifier were distributed as inter-hemispheric (44%), left intrahemispheric (25%), and right intra-hemispheric connections (31%) ( Fig. 2a-2b , Supplementary Results, and Table S5 ). The 16 FCs as SSD classifier were different from the 1 2
Specificity of the classifier to SSD regarding other psychiatric disorders
Separation of WLS distribution was largest between SSD and HC ( Fig. 3a) as already shown ( Fig. 1a ). In ASD, ADHD and MDD, the distribution was not distinguishable from HC (AUC = 0.50, Kolmogorov-Smirnov test, P = 0.57 for ASD; AUC = 0.57, P = 0.83 for ADHD; AUC = 0.55, P = 0.15 for MDD) (Fig. 3b-d) . These results suggest that on the biological dimension defined by the SSD classifier, ASD, ADHD and MDD were not close to SSD.
Relationships between SSD and ASD on the two biological dimensions
There were two main findings of relationships between SSD and ASD ( Fig. 4a and Supplementary Results). First, the center of the SSD population on ASD dimension was elevated to near 0.5 with respect to the center of its HC population, while the center of the ASD population on SSD dimension remained at zero, the same as the center of its HC population. Second, the SSD and ASD dimensional scores were significantly correlated in the ASD population (r = 0.28, P = 0.040, permutation test corrected for multiple comparisons), while there was no correlation in the SSD population. Most of the ASD classifier's FCs consistently contributed to the SSD-HC classification, but the FCs selected by the SSD classifier made inconsistent contributions to the ASD-HC classification, resulting in a cumulative WLS close to zero ( Fig. 4b and Supplementary Results). The first asymmetry finding was interpreted by the differences of contribution results. The cumulative sum of the correlation coefficients within the ASD population indicated a general positive trend ( Fig. 4c and Supplementary Results) , which was the same direction as the largest correlation. On the other hand, the sum of the correlation coefficients within the SSD population was close to zero, due to contradicting correlation coefficients. The second asymmetry finding was explained by these correlation coefficients analysis. Moreover, the number of FCs selected across LOOCV of the HC-SSD classification was more than double that of HC-ASD, and the 1 3
FC with the largest absolute weight in the SSD classifier (FC 1 SSD ) was selected in only 15% of the total LOOCV folds. These results were summarized in the schema ( Fig. 4d and Supplementary Results).
Discussion
To our knowledge, this is the first study to quantify overlapping, but asymmetrical relationships between SSD and ASD, by combining the categorical approach based on DSM and the dimensional approach based on brain connectivity. The sophisticated machinelearning algorithms using categorical diagnostic labels and whole brain rs-fMRI produced a classifier that could discriminate patients from HC. At the same time, the classifier generated a probabilistic degree of liabilities to SSD and ASD based on whole brain functional connectivity from the WLS distributions. The neural liability was so continuous that we could regard it as a biological dimension. Moreover, the biological dimension needs to be robust enough to have generalizability to independent cohorts, as the biological dimension should be compatible with diagnoses that are common in different cohorts. Here, we developed the SSD classifier by a similar method to that described for our previous ASD classifier 30 . The SSD classifier had generalizability to two independent cohorts in different countries and MRI machine vendors, not to other psychiatric disorders, and had specificity to chronic patients. Using these two classifiers, we could visualize individuals with ASD and SSD with their relative liability, and determine the overlapping, but asymmetrical relationships between SSD and ASD populations on the two biological dimensions. The relationships were more complicated than previously discussed in conceptual frameworks 2 .
The ASD classifier was developed in our previous study 30 , and here we focused on generating the SSD classifier. Various machine-learning algorithms have been applied 1 4
previously to develop SSD classifiers that could discriminate patients with SSD from HC [34] [35] [36] [37] [38] [39] .
However, none of the previous studies using only rs-fMRI tested whether the classifiers could present generalizability across different countries and MRI machine vendors. It was reported that there was a significant effect of MRI machine vendors 40 differences in FC patterns between chronic SSD and FES 42, 43 . Consequently, the finding that the SSD classifier did not generalize to FES might indicate that the classifier was specific to patients at a chronic stage of disease. In addition, we confirmed the specificity of the SSD classifier by demonstrating that it did not discriminate other psychiatric disorders from their respective control populations.
Plotting individuals with ASD, SSD, and HC on the dimensions along with DSM could show their heterogeneity based on functional neural circuits. A dimensional approach from only biological features using machine-learning algorithms could identify biotypes, but the biotypes were far from clinical diagnoses 13 . In contrast, our biological dimensions were compatible with DSM, and the continuous WLS distributions of ASD and SSD populations were matched to the current psychiatric approach in DSM known as "spectrum". Thus, our combined method of biological dimensions and the DSM system in this study may be useful in daily clinical work. Identifying a patient on the SSD-ASD dimensions may contribute to a clinician's medical decision-making.
5
Several alternate models about the relationship between ASD and SSD have been proposed 2 .
While these models were within conceptual frameworks, some studies that applied biological methods actually showed commonalities 4, 7 , or diametric conditions 44, 45 between the two disorders. We took advantage of the two biological dimensions of ASD and SSD, and revealed an overlapping, but asymmetrical relationships, which cannot be attained by a single dimension. The asymmetries here have dual meanings. First, the SSD population showed increased liability on the ASD dimension, while the ASD population did not on the SSD dimension. Increased ASD liability in the SSD population contributed to the substantial overlap between SSD and ASD populations (Fig. 4a) . Second, the two dimensions were correlated within the ASD population but not in the SSD population. The results from LOOCV underlying these asymmetries suggested that the network SSD is characterized by a larger diversity and that it partially shares information with the smaller network of ASD. This is in agreement with recent genetic evidences that ASD shares a significant degree of polygenic risk with SSD 4 , and that common genetic variations explain nearly 50% of total liability to ASD 46 and 25-33% of total liability to SSD 47 , suggesting that environmental factors play a significant role in the heterogeneous etiopathogenesis of schizophrenia 48 .
Limitations
First, the AUC of UMCU-TOPFIT (0.66) was lower than the AUC of COBRE (0.75). There was a difference in MRI raw data between 3D scan in UMCU-TOPFIT and 2D scan in COBRE. The classifier was developed from Kyoto datasets in 2D scan, and this might be related to the AUC difference. Second, almost all patients were on antipsychotic medication.
Previous studies reported that antipsychotics altered the functional connectivity in frontal and striatal circuits 49, 50 . Although we found no significant correlation between the SSD classifier 1 6
and antipsychotic medication (Supplementary Results), potential effects of antipsychotics on the SSD classifier cannot be entirely ruled out. Third, we did not recruit comorbid patients (ASD with psychosis), and we did not discuss comorbidity.
Conclusion
The current findings obtained by the two biological dimensions consisting of functional connectivity revealed asymmetrical and overlapping relationships between SSD and ASD. 
